SOVREMENNAYA PEDIATRIYA.2018.7(95):13-19; doi 10.15574/SP.2018.95.13

Shadrin O. G., Gaiduchik G. A., Sichel L.
State Institution «Institute of Pediatrics, Obstetrics and Gynecology named after academician E.N. Lukyanova National Academy of Medical Sciences of Ukraine », Kyiv
Pure Research Products, LLC, Boulder, Colorado, USA

Aims: the study of effectiveness of lyasates of lactic acid bacteria Lactobacillus rhamnosus V use in preschool children with food allergies.

Materials and Methods. 55 patients aged 2 to 6 years with food allergies were examined. 30 in the main group received lysate of lactic acid bacteria Lactobacillus rhamnosus V (Del-Immune V®) for two months at the age dosage as a part of complex therapy; and patients in comparison group received standard therapy. General clinical, immunological, allergological and bacteriological studies were conducted.

Results. Appointment of cell lysate of lactic acid bacteria Lactobacillus rhamnosus V strain resulted in significant decrease in frequency and severity of gastrointestinal, skin and respiratory manifestations of food allergy in children. In the main group, a significant decrease in concentration of eosinophilic cationic protein in blood serum, and increase in sIgA saliva concentration were registered in dynamics of treatment as compared with children in the comparison group. The positive effect on the state of intestinal microbiocenosis in children of the main group and the decrease in the frequency and duration of ARVI episodes against the background of lactic acid bacteria Lactobacillus rhamnosus V use was proved.

Conclusions. Complex therapeutic effect of lysates of lactic acid bacteria Lactobacillus rhamnosus V, absence of side effects and allergic reactions justify the expediency of their inclusion in the complex therapy of preschool children with food allergies.

Key words: preschool children, food allergy, lactic acid bacterium lysate Lactobacillus rhamnosus V, Del-Immune V®.

REFERENCES

1. Macharadze DSh. (2013). Klinicheskie osobennosti pischevoiy allergii u detei? Pediatriya. 92; 3: 110–116.

2. Okhotnikova OM. (2013). Hastrointestynalna kharchova alerhiia u ditei. Klinichna imunolohiia, alerholohiia, infektolohiia. Zbirnyk klinichnykh rekomendatsii. 2: 5–15.

3. Umanets TR, Shadrin OG, Klymenko VA et al. (2015). The main provisions of the guideline for the management of patients with the cow's milk allergy. Part III — diagnostics of cow's milk allergy. Sovremennaya pediatriya. 3(67):20–28. doi 10.15574/SP.2015.67.20

4. Haitov RM, Pinegin BV, Yarilin AA. (2009). Rukovodstvo po klinicheskoy immunologii: diagnostika zabolevaniy immunnoy sistemyi: rukovodstvo dlya vrachey. Moskva: GEOTAR-Media: 352.

5. Shadrin OG, Gayduchik GA, Kovalchuk AA et al. (2015). Optimization of treatment of gastrointestinal food allergy in infants. Perinatologiya i pediatriya. 3(63): 84–88. https://doi.org/10.15574/PP.2015.63.84

6. Burks A, Tang M, Sicherer S. et al. (2012). ICON. Food Allergy J. Allergy Clin. Immunol. 129: 906–920. https://doi.org/10.1016/j.jaci.2012.02.001; PMid:22365653

7. Elson G, Dunn-Siegrist I, Daubeuf B, Pugin J. (2007). Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood. 109:1574–1583. https://doi.org/10.1182/blood-2006-06-032961; PMid:17038528

8. Iliev ID, Kitazawa H, Shimosato T, Katoh S, Morita H et al. (2005). Strong immunostimulation in murine immune cells by Lactobacillus rhamnosus GG DNA containing novel oligodeoxynucleotide pattern. Cell Microbiol. 7: 403–414. https://doi.org/10.1111/j.1462-5822.2004.00492.x; https://doi.org/10.1111/j.1462-5822.2004.00470.x; PMid:15679843

9. Meyer R, Flemming C, Michaelis L. et al. (2012). Manifestations of gastrointestinal food allergies presenting to a single tertiary pediatric gastroenterology unit. J Pediatr. Gastroenterol. Nutr. (in press).

10. Nowak-Wegrzyn A. (2015, May-Jun). Food protein-induced enterocolitis syndrome and allergic proctocolitis. Allergy Asthma Proc. 36(3):172–84. https://doi.org/10.2500/aap.2015.36.3811; PMid:25976434 PMCid:PMC4405595

11. Takeda K, Akira S. (2005). Toll-like receptors in innate immunity. Int Immunol 17: 1–14. https://doi.org/10.1093/intimm/dxh186; PMid:15585605

12. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P et al. (2008). Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 118: 545–559. PMid:18188453 PMCid:PMC2176188

13. Wenink MH, Santegoets KC, Broen JC, van Bon L, Abdollahi-Roodsaz S et al. (2009). TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop. J Immunol. 183: 6960–6970. https://doi.org/10.4049/jimmunol.0900713; PMid:19915052

14. Windheim M, Lang C, Peggie M, Plater LA, Cohen P. (2007). Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochem J. 404: 179–190. https://doi.org/10.1042/BJ20061704; PMid:17348859 PMCid:PMC1868792

Article received: Jun 11, 2018. Accepted for publication: Nov 15, 2018.